----
Current ValuationThe current P/E ratio is -37.36, below the reasonable range, cheaper than 97.47% of the time in the past 5 years, and the industry ranks 32/38, the industry Median -0.95.
-37.36xP/E
$27.14Stock price
$-0.73Earnings per share
-37.36xP/E
Stock price$27.14Earnings per share$-0.73
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -8.70x
- Typical range
- -13.22x–36.45x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -43.38x | 74.45% | $5.13B |
SDGRUSSchrodinger | -37.36x | 16.60% | $2.03B |
CERTUSCertara | -24.57x | 2,116.80% | $1.68B |
TDOCUSTeladoc | -9.99x | 26.96% | $1.55B |
MDRXUSVeradigm | -- | -- | $851.43M |
SOPHUSSophia Genetics SA | -8.03x | 19.83% | $649.53M |
EVHUSEvolent Health | -0.95x | 84.41% | $486.16M |
CTEVUSClaritev | -1.44x | 12.62% | $406.74M |
AMWLUSAmerican Well | -2.77x | 57.74% | $216.52M |
DHUSDefinitive Healthcare | -0.96x | 21.33% | $162.22M |
HCATUSHealth Catalyst | -0.48x | 4.22% | $127.18M |
LFMDUSLifeMD | -37.99x | 195.82% | $110.38M |
VSEEUSVSee Health | -8.51x | -- | $84.19M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -3.15x | -- | $44.66M |
DRIOUSDarioHealth | -4.20x | 60.40% | $29.38M |
ONMDUSOneMedNet | -2.97x | -- | $25.02M |
ITOCUSiTonic | -2.13x | -- | $19.02M |
AIFFUSFirefly Neuroscience | -1.66x | -- | $15.69M |
BFRGUSBullfrog AI | -1.51x | 41.27% | $9.04M |
HLYKUSHealthLynked Corp. | -1.44x | -- | $5.76M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
